0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Comparison of Serotonin Receptor Numbers and Activity in Specific Hypothalamic Areas of Sexually Active and Inactive Female Rats

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In a previous study we have shown that a positive correlation exists between 5-hydroxytryptamine (5-HT) activity and female sexual receptivity in the pre-optic area (POA) and median eminence (ME) and that there is a negative correlation in the ventromedial nucleus (VMN), zona incerta (ZI) and arcuate nucleus (ARC). In this report, the possibility that 5-HT receptor density and affinity alter with sexual receptivity has been investigated. Micropunches of the POA, VMN, ARC, ME and the anterior hypothalamus were dissected from ovariectomised rats primed with a submaximal steroid regime (2 µg oestradiol benzoate, OB, followed at 48 h by 0.05 mg progesterone) which induced receptivity (lordosis quotient, LQ, 80–100%) in approximately half the animals, the remaining half usually exhibiting an LQ < 20%. Binding studies were carried out using <sup>3</sup>H-ketanserin (5-HT<sub>2A</sub> ligand) and <sup>3</sup>H-8-hydroxy-2-(di-n-propylamine)tetraline (8-OHDPAT; 5-HT<sub>1A</sub> ligand) and pooled (n = 5) micropunch samples. The B<sub>max</sub> of 5-HT<sub>2A</sub> receptors in the sexually receptive groups was significantly (p < 0.05) greater in the POA and ME and significantly lower in the VMN, ARC and ZI when compared with values in the non-receptive animals. The K<sub>D</sub> values of the 5-HT<sub>2</sub>A receptors did not differ in the two groups (except the ZI, where the K<sub>D</sub> was lower in receptive rats). Neither the B<sub>max</sub> nor K<sub>D</sub> of the 5-HT<sub>1A</sub> receptors differed in the two groups in any area investigated. Administration of the 5-HT<sub>2</sub> agonists dimethoxyiodophenylaminopropane and m-chlorophenyl piperazine into the POA resulted in enhanced sexual activity in animals exhibiting a low level of receptivity, after 5 µg OB given alone while ketanserin (5-HT<sub>2A</sub> antagonist) in the POA inhibited sexual activity in receptive animals primed with the submaximal steroid regime given above. In the same models, neither the 5-HT<sub>2</sub> agonists nor the 5-HT<sub>2</sub>A antagonist affected behaviour when applied to the VMN. The 5-HT<sub>1A</sub> agonist 8-OHDPAT exerted an inhibitory effect in the VMN. These findings, together with earlier results, show that in receptive animals there is an increase in both 5-HT turnover and 5-HT<sub>2A</sub> receptors in the POA and ME. Additionally 5-HT<sub>2</sub> agonists and an antagonist applied to the POA enhance and reduce sexual activity, respectively. This suggests that the 5-HT<sub>2</sub> system in the POA has a stimulatory role in the control of female sexual behaviour. Both 5-HT activity and 5-HT<sub>2</sub> receptors are decreased in the VMN, ARC and ZI of receptive animals. 5-HT<sub>2</sub> agonists and a 5-HT<sub>2A</sub> antagonist have no effect in the VMN indicating that there is no 5-HT2-stimulatory or -inhibitory effect in this area, at least in the animal models used in these experiments. However, the VMN is a site of an inhibitory action mediated by the 5-HT<sub>1A</sub> receptors.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1997
          1997
          09 April 2008
          : 66
          : 6
          : 384-392
          Affiliations
          aDepartment of Obstetrics and Gynaecology, St. George’s Hospital Medical School, London, and bPfizer Central Research Ltd., Sandwich, UK
          Article
          127277 Neuroendocrinology 1997;66:384–392
          10.1159/000127277
          9430444
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Categories
          Neuroanatomy and Regulation of Hypothalamic Neurons

          Comments

          Comment on this article